Total Visits

Views
Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in measures of disease activity in patients with psoriatic arthritis: Results from 3 phase 3, randomized, controlled trials5

Select a period of time:

Number of views in the range

Views

Top country views

Views
 

Top cities views

Views